These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 4416021)

  • 21. A phase 2 study of intermittent high dose isophosphamide therapy of advanced colorectal cancer.
    Kovach JS; Schutt AJ; Hahn RG; Reitemeier RJ; Moertel CG
    Oncology; 1974; 29(1):34-9. PubMed ID: 4837137
    [No Abstract]   [Full Text] [Related]  

  • 22. Absence of cross-resistance to alkylating agents in cyclophosphamide-resistant L1210 leukemia.
    Wampler GL; Regelson W; Bardos TJ
    Eur J Cancer (1965); 1978 Sep; 14(9):977-82. PubMed ID: 710488
    [No Abstract]   [Full Text] [Related]  

  • 23. [Pharmacological studies with alkylsulfonyloxyalkyl substituted and chloroethyl substituted oxazaphosphorine-2-oxides. 2. Pharmacological characterization of 2-alkylsulfonyl-oxyalkylamino-oxazaphosphorine-2-oxides including immunological reaction].
    Arzneimittelforschung; 1974 Aug; 24(8):1149-60. PubMed ID: 4371545
    [No Abstract]   [Full Text] [Related]  

  • 24. Synthesis and antitumor activity of preactivated isophosphamide analogues bearing modified alkylating functionalities.
    Takamizawa A; Matsumoto S; Iwata T; Makino I; Yamaguchi K; Uchida N; Kasai H; Shiratori O; Takase S
    J Med Chem; 1978 Feb; 21(2):208-14. PubMed ID: 621716
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Comparison of ifosfamid with cyclophosphamide in the therapy of rat DS carcinosarcoma].
    von Ardenne M; Reitnauer PG; Rohde K
    Arch Geschwulstforsch; 1971; 38(1):15-26. PubMed ID: 4334130
    [No Abstract]   [Full Text] [Related]  

  • 26. Quantitative GLC determination of cyclophosphamide and isophosphamide in biological specimens.
    Pantarotto C; Bossi A; Belvedere G; Martini A; Donelli MG; Frigerio A
    J Pharm Sci; 1974 Oct; 63(10):1554-8. PubMed ID: 4436788
    [No Abstract]   [Full Text] [Related]  

  • 27. [Diagnosis and treatment of panarteritis in childhood].
    Kühner U; Ackermann R; Frohmüller H
    Klin Padiatr; 1972 Sep; 184(5):399-408. PubMed ID: 4404493
    [No Abstract]   [Full Text] [Related]  

  • 28. Some novel potential alkylating agents derived from diethylstilbestrol.
    Roushdi IM; Omar AM; Ragab MS; Awad M
    J Med Chem; 1976 Nov; 19(11):1333-6. PubMed ID: 1003412
    [No Abstract]   [Full Text] [Related]  

  • 29. Unexpected toxicity in patients treated with iphosphamide.
    Van Dyk JJ; Falkson HC; Van der Merwe AM; Falkson G
    Cancer Res; 1972 May; 32(5):921-4. PubMed ID: 4552918
    [No Abstract]   [Full Text] [Related]  

  • 30. Synthesis of new bis(1-aziridinyl) phosphinate alkylating agents containing O-phenyl N-phenylcarbamate side chains.
    Hsiao YY; Bardos TJ
    J Med Chem; 1973 Apr; 16(4):391-4. PubMed ID: 4716182
    [No Abstract]   [Full Text] [Related]  

  • 31. Immunosuppressive properties of cyclophosphamide analogues.
    Harrison EF; Fuquay ME
    Proc Soc Exp Biol Med; 1972 Mar; 139(3):957-63. PubMed ID: 5063370
    [No Abstract]   [Full Text] [Related]  

  • 32. Potential bis-alkylating agents for cancer chemotherapy. Approaches to the synthesis of 2-sulfonyl-1,4-bis(methanesulfonoxy)butanes.
    Wilbur JM
    J Med Chem; 1978 Nov; 21(11):1168-71. PubMed ID: 214556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Experiences with single high dosage iphosphamide therapy in metastasizing malignant neoplasms].
    Drings P; Fritsch H
    Verh Dtsch Ges Inn Med; 1972; 78():166-9. PubMed ID: 4353153
    [No Abstract]   [Full Text] [Related]  

  • 34. New drugs on the horizon in bronchogenic carcinoma.
    Carter SK
    Cancer; 1972 Nov; 30(5):1402-9. PubMed ID: 4117256
    [No Abstract]   [Full Text] [Related]  

  • 35. 1,2-bis(arylsulfonyl)hydrazines. 2. The influence of arylsulfonyl and aralkylsulfonyl substituents on antitumor and alkylating activity.
    Shyam K; Furubayashi R; Hrubiec RT; Cosby LA; Sartorelli AC
    J Med Chem; 1986 Jul; 29(7):1323-5. PubMed ID: 3806585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Toxicity and antitumor activity of the antibiotic rubomycin and dipin in combination with diuretics (diacarb)].
    Stepanova ES
    Antibiotiki; 1976 Mar; 21(3):262-6. PubMed ID: 946939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential anticancer agents. 10. Synthesis of N-(4((2,4-diamino-7-pteridyl)methyl)-N10-methylamino)benzoyl)glutamic acid.
    Suster DC; Feyns VL; Ciustea G; Botez G; Dobre V; Bick R; Niculescu-Duvăz I
    J Med Chem; 1974 Jul; 17(7):758-60. PubMed ID: 4836410
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of "3-oxauracil" (2,3-dihydro-1,3-6H-oxazine-dione) in L1210 leukemia.
    Ujházy V; Reiner P; Farkas J; Skoda J
    Neoplasma; 1977; 24(3):259-61. PubMed ID: 895936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical conference: facial paralysis. Grand rounds. Massachusetts Eye and Ear Infirmary.
    Schuknecht H; Goodman ML; Weber A; Pappanikou A; Tolpin D
    Ann Otol Rhinol Laryngol; 1974; 83(2):257-63. PubMed ID: 4817439
    [No Abstract]   [Full Text] [Related]  

  • 40. Mutagenic and chemotherapeutic activity in L1210 leukemia of several monofunctional alkylating agents.
    Wheeler GP; Adamson DJ; Webster J
    Cancer Res; 1985 Jul; 45(7):3400-2. PubMed ID: 4005864
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.